Pfizer remains a strong buy due to its undervalued stock, robust drug pipeline, and aggressive growth in oncology and obesity treatments. The company reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and EPS of $2.8–$3 despite patent expirations. Key strategies include onshoring high-margin production and aggressive cost-cutting to mitigate risks from patent losses and improve operating margins through 2027. With a price-to-earnings ratio of 8.13 and a 6.4% dividend yield, Pfizer offers compelling value compared to peers, though risks remain around patent cliffs and execution of its obesity platform.
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
